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ABSTRACT 
LIM proteins constitute a superfamily characterized by the presence of specialized 
domains called LIM. LIM domain is a unique double-zinc finger motif found in a variety 
of proteins and is mainly involved in protein-protein interactions. Previous work has 
implicated that members of the Zyxin subfamily of LIM proteins, namely TRIP6 and LPP 
are involved in the repression of the DNA damage response (DDR) at telomeres. We 
further explore if another member from this family has an influence on DDR prevention 
in the cells. Here, we describe a novel role for Ajuba, a Zyxin family LIM protein, in 
repressing inappropriate activation of ATR kinase mediated DDR. We found that 
depletion of Ajuba led to a decrease in cell proliferation, apparent delay in the cell cycle, 
accompanied with increased phosphorylation of Retinoblastoma protein (Rb). We detect 
that reduction of Ajuba leads to Chk1 phosphorylation, indicative of ATR activation in 
cells. We also observe induction of p53 and cell death by apoptosis in the Ajuba depleted 
cells. The phenotypic effects of Ajuba depletion are observed in cancer as well as in non-
cancer cells types. Ajuba could be found in a complex with replication protein A (RPA). 
Ajuba depletion led to RPA phosphorylation, which is known to be an early event in 
ATR activation. We propose that Ajuba exerts its function through its interaction with the 
RPA complex, preventing undesirable RPA phosphorylation in the absence of exogenous 
insults, and thereby repressing an inappropriate ATR activation.  
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CHAPTER 1: INTRODUCTION 
GENOMIC INTEGRITY 
During the lifecycle of an organism several endogenous events and exogenous agents can 
inflict damage to the cellular DNA and can severely jeopardize its genomic integrity. To 
counteract the deleterious effect of these actions and to maintain genomic integrity, 
evolutionarily conserved cellular pathways have evolved. DNA damage response (DDR) 
is one such mechanism that ensures efficient repair of all types of damage, including 
individual DNA base lesions and breaks. In addition to repair, DNA damage may activate 
other cellular responses including cell cycle arrest and apoptosis. Proper inheritance of 
genetic material is also controlled by elaborate cell cycle stages coordinated by various 
regulatory proteins. Recent research has shown, that the biological processes of DNA 
replication, DNA damage, cell cycle cannot be considered as isolated cellular functions. 
All these pathways exhibit crosstalk, forming a network in which disruption of one 
pathway leads to recruitment of others to protect genome integrity and maintain cell 
homeostasis. Failure to protect genomic material may lead to accumulation of DNA 
damage and loss of genomic integrity leading to changes in gene expression, associated 
with early tumorigenesis (Bartkova, Horejsi et al. 2005, Gorgoulis, Vassiliou et al. 2005). 
CELL CYCLE CONTROL AND CANCER 
Cell division accuracy is crucial in maintaining genomic stability. Cell cycle progression 
is controlled by holoenzymes made up of the regulatory cyclins and catalytic cyclin-
dependent kinases (CDKs). Specific cyclins and corresponding CDKs form complexes 
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called cyclin-CDK (cyclin-dependent kinases) complexes resulting in the activation of 
CDKs. In mammalian cells, multiple CDKs and cyclins that regulate passage through the 
cell cycle can be classified to four main groups by the stage of cell cycle- Mid G1: 
CyclinD-CDK4/6, Late G1: Cyclin E-CDK2, S phase: Cyclin A-CDK2, Mitotic phase: 
CyclinA/B-CDK1. In response to DNA damage, the cell cycle is temporarily paused 
before S phase, thereby preventing replication of the damaged DNA. Once replication has 
started, the intra-S checkpoint can be activated by replication stress. Both the G1/S and 
the intra-S checkpoints ensure that replication is stopped until DNA damage has been 
repaired (Bartek and Lukas 2007). DNA damage that has remained undetected by these 
checkpoints or has occurred during the G2 phase may activate the G2/M checkpoint. This 
checkpoint stalls the cell cycle in response to DNA damage and prevents entry into 
mitosis (Kastan and Bartek 2004). Molecular studies have revealed that cell cycle 
regulators are frequently mutated in many human tumor cells. Most prominent among the 
regulators that are found mutated in cancer cells are two tumor suppressors, the 
retinoblastoma protein (RB) and the p53 transcription factor (Sherr and McCormick 
2002). The aberrant regulation of the cyclins and CDKs in cancer cells help bypass the 
normal cell cycle regulation resulting in the uncontrolled cell division (Malumbres and 
Barbacid 2001).  
DNA DAMAGE RESPONSE 
The DNA damage response (DDR) is a signal transduction pathway that senses DNA 
damage and replication stress and sets in motion an organized response to protect the cell 
(Ciccia and Elledge 2010). A complex network of proteins is activated on induction of 
DNA damage. In a generalized view, sensor proteins recognize lesions and localize to 
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sites of DNA damage. These in turn activate and recruit transducer proteins to the sites, 
which phosphorylate effectors or mediator proteins that influence cell activity. There are 
multiple cellular responses to DDR activation. One of them is cell cycle arrest (Petrini 
and Stracker 2003), allowing time for DNA repair to occur, thereby preventing genome 
duplication or cell division in the presence of damaged DNA. In addition, the DNA 
damage response may induce cell death via apoptosis or cause cellular senescence (von 
Zglinicki, Saretzki et al. 2005).  
PHOSPHATIDYLINOSITOL (PI) 3-KINASE RELATED KINASES 
DDR causes activation of a network of signaling reactions that modulate cell cycle 
progression, gene expression and protein synthesis. Protein kinases belonging to the 
phosphatidylinositol (PI) 3-kinase related kinase (PIKK) family are major players in the 
detection, signaling and repair of DNA damage (Abraham 2004). The PIKK family 
contains unconventional serine/threonine kinases that are large proteins and are 
structurally different from classical protein kinases, but whose kinase domains more 
closely resemble those of the PI 3-kinase family of phospholipid kinases. There are six 
members in the family. Mammalian target of rapamycin (mTOR) senses and integrates a 
variety of environmental cues to regulate cell growth and proliferation. Human 
suppressor of morphogenesis in genitalia-1 (hSMG-1) is involved in nonsense-mediated 
mRNA decay (NMD) as part of the mRNA surveillance complex. 
Transformation/transcription domain- associated protein (TRRAP) is an essential 
component of the histone acetyl transferase complexes. DNA-dependent protein kinase 
(DNA-PKcs) help in repair of double stranded breaks by non-homologous end 
joining  (NHEJ) pathway of DNA repair. The ataxia-telangiectasia mutated (ATM) 
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kinase signaling cascade is activated mainly in response to DNA double strands breaks 
(DSBs) and ATM and Rad3-related (ATR) kinases is mainly activated upon single 
stranded DNA breaks (SSBs) (Abraham 2004, Liu, Opiyo et al. 2012). Both ataxia-
telangiectasia mutated (ATM) and ATM and Rad3-related (ATR) kinases have a major 
role in the apex of a DNA damage response and are crucial in preserving genomic 
stability (Shiloh 2003). The ATM-Chk2 signaling cascade is activated mainly in response 
to DNA double strands breaks (DSBs). The MRE11-RAD50-NBS1 (MRN) sensory 
complex recognizes the break and recruits ATM to the DSBs (van den Bosch, Bree et al. 
2003, Paull and Lee 2005). ATM phosphorylates Chk2 and activated Chk2 is thought to 
dissociate from sites of damage and disperse throughout the nucleus to act on multiple 
substrates involved in cell cycle progression, apoptosis, and gene transcription (Shiloh 
2003). In humans, mutations in the ATM gene cause ataxia-telangiectasia syndrome. It is 
an autosomal recessive trait; hence people with this disorder have mutations in both 
copies of the ATM gene. ATM mutations cause inappropriate cell death and affects brain 
cells involved in coordinating movements (the cerebellum). This loss of brain cells 
causes movement problems, characteristic of ataxia-telangiectasia. Because of its central 
role in cell division and DNA repair, the ATM protein has implication in cancer research. 
ATR mediated DNA damage response 
Gene knockout studies show that ATR is essential for somatic cell growth and genomic 
integrity in the embryo and that its deletion leads to genomic disruption and early 
embryonic lethality in mice. Homozygous loss-of-function mutations in ATR gene are 
not compatible with mammalian cell viability (Brown and Baltimore 2000, de Klein, 
Muijtjens et al. 2000). However, hypomorphic mutations in ATR gene that cause reduced 
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ATR function are found in a few patients with the rare Seckel syndrome, which is 
characterized by microcephaly and growth retardation (O'Driscoll, Ruiz-Perez et al. 
2003). ATR signaling is strongly activated by single stranded breaks (SSBs) formed 
during DNA replication impairment, nucleotide excision repair (NER) or dysfunctional 
telomeres (Figure 1). When replication is blocked, DNA polymerases become uncoupled 
from the replicative helicase (Byun, Pacek et al. 2005) and the helicase continues to 
unwind DNA in front of the fork and generate regions of ssDNA that are rapidly coated 
with ssDNA-binding protein complex, Replication Protein A (RPA). RPA2, a subunit of 
RPA is rapidly phosphorylated by number of PIKKs including ATR kinase upon 
replication stress.  ATR is recruited to these sites and is activated by associating with its 
partner protein, ATR interacting protein (ATRIP), which interacts directly with ssDNA 
complexed with RPA (Zou and Elledge 2003). ATR is autophosphorylated at Thr 1989, 
and is crucial for its activation. Phosphorylation of Thr 1989 relies on RPA, ATRIP, and 
ATR kinase activity (Liu, Shiotani et al. 2011). Although RPA-ssDNA may be sufficient 
for localizing the ATR-ATRIP complex, it is not sufficient for ATR activation. Efficient 
ATR activation also depends on the actions of mediator proteins like TopBP1 and RAD9: 
RAD1: HUS1 (9-1-1) complex. Thr 1989 residue on ATR is directly recognized by 
TopBP1, enabling TopBP1 to engage ATR-ATRIP. TopBP1 is recruited to ssDNA-RPA 
via the PCNA-like RAD9: RAD1: HUS1 checkpoint clamp (Delacroix, Wagner et al. 
2007) and contains a domain that stimulates ATR activity. Loading of the 9-1-1 complex 
occurs at a DNA end that is adjacent to a stretch of RPA-ssDNA. Presence of RPA is 
critical for loading of 9-1-1 clamp on the dsDNA adjacent to the RPA bound ssDNA. 
Checkpoint kinase 1 (Chk1) kinase, a major downstream target of ATR is phosphorylated 
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by activated ATR (Zhao and Piwnica-Worms 2001). Chk1 is not only important for the 
checkpoint response, but is also crucial for preventing replication initiation and the 
stability of DNA replication forks (Heffernan, Simpson et al. 2002). Phosphorylation of 
Chk1 results in cellular effects such as modulation of Cell division cycle 25 (Cdc25) 
phosphatases causing checkpoint mediated cell cycle arrest in S and G2 phases 
(Sorensen, Syljuasen et al. 2003). Both ATM and ATR phosphorylate Ser15 of p53 
directly and Ser20 through activation of Chk2 or Chk1 (Chehab, Malikzay et al. 1999, 
Shieh, Ahn et al. 2000, Serrano, Li et al. 2013). p53 activation is crucial for many cellular 
processes including DNA repair, cell cycle arrest and apoptosis.  
 
FIGURE 1: ATR MEDIATED DNA DAMAGE RESPONSE 
ssDNA is formed during replication stress. RPA binds to ssDNA, which then recruits 
ATR-ATRIP by interacting with ATRIP. RPA may also work with RAD17-RFC (not 
shown) to load the 9-1-1 (RAD9-RAD1-HUS1) checkpoint clamp to the 5′ recessed 
junction. TopBP1 interacts with ATRIP-ATR and phosphorylated Rad9 from the 9-1-1 
clamp. The ATR-activating domain of TopBP1 stimulates the kinase activity of ATR. 
ATR can phosphorylate the effector kinase Chk1 to activate it. Chk1 phosphorylates 
Cdc25 phosphatases to inactivate them, thus causing cell cycle delay. Chk1 can also 
phosphorylate p53 and aid in downstream effects like apoptosis and DNA repair. 
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ATM and ATR kinases are stimulated with distinct type of DNA damage and seem to be 
proximal acting proteins of independent but parallel pathways, however data from several 
laboratories indicate that the pathways are interconnected and act in co-ordination in 
response to DNA damage. Studies show that ATR kinase is activated in response to 
DSBs in an ATM dependent manner and ATR activators can also activate ATM in an 
ATR dependent way (Hurley and Bunz 2007, Yan, Sorrell et al. 2014). 
DDR DURING TELOMERE DE-PROTECTION  
DDR can also occur at deprotected telomeres. Telomeres are chromosome ends and 
represent sensitive sites that resemble DNA damage sites if left unprotected. The 
presence of a six- protein complex called Shelterin at telomeres serves the purpose of 
protecting the telomeres. Telomeres are composed of 2-12 kb of TTAGGG repeats and 
end in a ssDNA overhang of about 150 nucleotides (Palm and de Lange 2008). Shelterin 
proteins are able to restrain telomere recombination, Non homologous end joining 
(NHEJ) and homologous recombination (HR) (Wu, Multani et al. 2006). Activation of 
DDR at telomeres leads to chromosome end to end fusions by NHEJ, followed by p53 
mediated cell cycle arrest and apoptosis. In p53 negative MEFs, extensive chromosome 
fusions and rearrangements are observed (Karlseder, Broccoli et al. 1999). 
The Shelterin complex on the telomere has TRF1 and TRF2, which bind double stranded 
DNA directly through a MYB-type DNA binding domain. TRF2 plays a key role in 
suppressing the telomere-associated DDR through its DNA binding and inhibition of 
ATM kinase. In ATM null cells, the formation of TIFs and phosphorylation of Chk2 in 
response to TRF2 deletion were largely abrogated (Karlseder, Hoke et al. 2004, Denchi 
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and de Lange 2007). Another shelterin protein, TIN2 has the ability to interact with both 
TRF1 and TRF2 simultaneously, and recruits TPP1/POT1 to the complex. TIN2 is 
required for TPP1/POT1 function at telomeres (Takai, Kibe et al. 2011). TPP1 recruits 
POT1 and also has a recruitment domain for telomerase, thus providing a link between 
the enzyme and telomeres. Shelterin protein POT1 binds to the telomeric single stranded 
overhang through its N- terminal OB (oligonucleotide/oligosaccharide) folds (Loayza and 
De Lange 2003). Deletion of POT1 causes accumulation of 53BP1 foci at telomeres 
(Hockemeyer, Sfeir et al. 2005) and POT1 was found to protects against inappropriate 
ATR activation (Denchi and de Lange 2007). Deletion of POT1 orthologs (POT1a and 
POT1b) in mouse embryonic fibroblast (MEFs) led to embryonic lethality (Hockemeyer, 
Daniels et al. 2006). When POT1a was conditionally deleted from mouse cells, activation 
of the ATR checkpoint was observed (Denchi and de Lange 2007). Furthermore, upon 
POT1a depletion, the amount of RPA increased at telomeres, suggesting that POT1a 
antagonizes the binding of RPA to telomeric ssDNA (Gong and de Lange 2010). Similar 
to mouse cells, knockdown of POT1 in human cells also resulted in accumulation of RPA 
at telomeres (Flynn, Centore et al. 2011). This ability of POT1 to prevent RPA binding is 
important to represses ATR activation at telomeres. Taken together, TRF2 and POT1 
function independently to repress ATM and ATR mediated DNA damage respectively 
(Figure 2).  
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FIGURE 2: ROLE OF SHELTERIN IN ATR AND ATM REPRESSION AT 
TELOMERES 
Figure modified from (de Lange 2005). Schematic representation of Shelterin protein 
complex at mamalian telomeres. POT1 and TRF2 inhibit the unscheduled activation of 
ATR and ATM kinase pathway respectively. 
 
REPLICATION PROTEIN A (RPA) 
While POT1 specifically recognizes single stranded telomeric repeats, RPA binds to 
ssDNA in a non-sequence-specific manner. RPA plays a key role in DNA replication and 
activation of the ATR checkpoint. RPA is the major eukaryotic ssDNA binding protein, 
which plays a critical role in DNA replication, recombination and repair. RPA protects 
ssDNA from reanneling and from nucleases through direct DNA binding. It also helps 
co-ordinate formation of protein complexes essential for cell processes such as DNA 
replication and repair. RPA is a heterotrimeric protein made of RPA1 (RPA70), RPA2 
ATM$kinase$
ATR$kinase$
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(RPA32) and RPA3 (RPA14) subunits with molecular weight of 70 kD, 32 kD, and 14 
kD respectively. A significant structural feature of RPA is the presence of the OB 
(oligonucleotide/oligosaccharide binding) folds within its subunits. OB-fold is a five-
stranded closed β barrel structure that can wrap around ssDNA. RPA70 consists of four 
OB folds, two of which comprise the central DNA binding domain, RPA32 and RPA14 
have a single OB fold (Wold 1997). The OB fold of RPA14 is not required for DNA 
binding activity but contribute to the complex stability. The N-terminal domain of 
RPA70 directly interacts with several checkpoint proteins, including ATR (through 
ATRIP), Rad17-Replication Factor C (RFC), p53, and Rad9 (Xu, Vaithiyalingam et al. 
2008) to promote ATR signaling. 
N-terminal of RPA32 has 33 residues that are mainly phosphorylated during cell cycle 
progression and in response to DNA damage by members of PIKK family and cyclin-
Cdk complexes (Binz, Sheehan et al. 2004). Out of the 33 sites, PIKK family members 
like ATM, ATR, and DNA-PK phosphorylate residues Thr21 and Ser33(Olson, Nievera 
et al. 2006, Anantha, Vassin et al. 2007) on DNA damage. Phosphorylated RPA recruits 
ATR to ssDNA through an interaction with ATRIP (Zou and Elledge 2003). 
Phosphorylation of RPA helps regulate its function by altering its interaction with other 
key proteins in the DNA damage response pathway (Binz, Sheehan et al. 2004, Vassin, 
Anantha et al. 2009). 
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FIGURE 3: SCHEMATIC DIAGRAM OF DOMAIN STRUCTURE OF RPA 
Figure modified from (Fanning, Klimovich et al. 2006).  Diagram shows OB-folds in 
blue boxes; arrows indicate intersubunit associations; protein-binding domains are 
denoted by red bars; ssDNA binding domains A–D by hatching; linkers by yellow boxes; 
winged helix by a green box; phosphoamino acid cluster by a circled P  
 
LIM DOMAIN PROTEINS 
LIM domain proteins were first discovered as transcription factors in Caenorhabditis 
elegans and their name stems from the initials of the three homeodomain proteins in 
which they were identified in; Lin11, Isl-1 and Mec-3. LIM domains are highly 
conserved among species and are found in more than 60 gene products in humans 
(Kadrmas and Beckerle 2004). Each LIM domain is made of 50-60 amino acids and 
consists of two zinc finger motifs separated by two amino acids (Figure 4B). The two 
zinc fingers have 8 conserved amino acids and are rich in cysteines, histidines and 
aspartic acid residues that are coordinately bonded with two zinc atoms (Figure 4A). A 
broad consensus sequence of LIM domains has been defined as 
  12 
CX2CX16−23HX2CX2CX2CX16−21CX2(C/H/D) (where X denotes any amino acid). 
Zinc finger containing proteins are mainly known for their DNA binding properties but 
LIM domains proteins are distinct from other Zn finger proteins, as their Zn finger 
domains are primarily involved in protein-protein interactions. LIM proteins are broadly 
classified in four categories depending upon the arrangement and position of the LIM 
domains as well as cellular localization (Figure 4C). Category one has characteristics of 
having two tandem N-terminal LIM domains and is localized in the nucleus. This group 
consists of LHX (LIM homoeodomain) and nuclear LMO (LIM-domain-only) proteins. 
The proteins in this group include the three founder members and other nuclear 
transcription factors involved in cell fate determination and differentiation. Group 2 
proteins are LIM-only (LMO) proteins found both in the nucleus and cytoplasm and can 
contain one to five LIM domains at the N or C-termini. Group 3 has three to four tandem 
LIM domains located at the C terminus and a unique N terminus containing various other 
protein–protein interaction motifs.  The proteins in this category can be nuclear, 
cytoplasmic or both. Some members of group 3 include Zyxin, Lipoma partner protein 
(LPP), Trip6 and Ajuba. This group is of particular interest to my thesis, as our lab 
focuses on studying the role of these proteins at human telomeres as well as determining 
their role in DDR. Group 4 proteins are similar to group 3 proteins but they also contain a 
catalytic domain (Kadrmas and Beckerle 2004, Zheng and Zhao 2007). 
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FIGURE 4: LIM DOMAIN TOPOLOGY AND CLASSIFICATION  
Figure from (Kadrmas and Beckerle 2004, Zheng and Zhao 2007). (A) The spacing of the 
eight zinc-binding residues (1-8) is based on analysis of 135 human LIM sequences. 
Occasionally observed patterns (seen in <10% of cases) are represented in characters that 
are not bold. Here, X denotes any amino acid. (B) Topology od LIM domain shown with 
Zn binding residues (1-8). Green circles represent aliphatic/bulky residues. Magenta 
circles indicate non-conserved residues and dashed yellow circles show possible variable 
residues. LIM domains are 50-60 amino acids long and characterized by two Zinc finger 
domains separated by two amino acids. (C) LIM domain proteins are roughly classiﬁed 
into four groups corresponding to the organization of LIM domains. Individual LIM 
domains are shown as black quadrangles; other domains are shown as white quadrangles 
and indicated respectively on the Figure. ActA, ActA repeat region; CH, calponin 
homology; G, glycine rich region; HD: homeodomain; PET, prickle, espinas and testin; 
PEST, Pro-Glu-Ser-Thr sequence; NebR, Nebullin repeats; SH3, Src homology-3; VHP, 
villin head piece. 
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LIM proteins are involved in different biological processes by acting as protein binding 
platforms and thereby inducing a change in the activity of their binding partner. Research 
based on the various protein interactions involving LIM domains highlight four main 
functions of LIM proteins. They can act as adaptors, competitors, localizers and 
autoinhibitors (Figure 5). LIM proteins can function as adaptors or scaffolding proteins 
when they possess additional protein interacting domains (Figure 5A). These proteins 
help in assembly of large multimeric protein complexes by bringing proteins in close 
proximity and thus impacting their activity.  LIM proteins can also act as competitors for 
binding partners and control the biological activity of the associated protein (Figure 5B). 
Conformational changes in LIM proteins can also influence its activity and have an effect 
on the biological function. The inhibitory domains modulate the activity of other domains 
in the same protein through intramolecular interactions (Kadrmas and Beckerle 2004).  
Lastly, LIM domains can control subcellular localization of the binding partners as well 
as themselves. This function is particularly interesting because LIM proteins that are 
known to have a cytoplasmic function can interact with its binding partners to translocate 
in the nucleus, where it has a completely different role to play than the cytoplasmic 
function (Kanungo, Pratt et al. 2000). Thus a same LIM protein is able to perform 
different functions depending upon its subcellular localization and protein interactions. 
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FIGURE 5: LIM DOMAIN FUCTIONS 
Figure from (Kadrmas and Beckerle 2004) (A) Adaptors are involved in assembly of 
protein complexes by serving as binding platform or scaffold. (B) LIM domain proteins 
can compete with other LIM proteins for binding partners regulating its activity. (C) 
Conformational change in LIM domain proteins can lead to autoinhibition through 
intramolecular interactions. There is difference in activity in open or closed 
conformation. (D) Change in cellular localization on interaction with binding partners.  
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Zyxin family of LIM proteins 
The Zyxin protein family contain six members- Ajuba, LIM domain containing protein 1 
(LIMD1), Wilms tumour 1 interacting protein (WTIP), Zyxin, Lipoma preffered partner 
(LPP) and Thyroid hormone interacting protein 6 (Trip6) (Crawford and Beckerle 1991, 
Petit, Mols et al. 1996, Yi and Beckerle 1998, Goyal, Lin et al. 1999, Kiss, Kedra et al. 
1999, Wang and Gilmore 2001). All protein members from this family contain three 
tandemly arranged homologous LIM domains at the C-terminus and a non-homologous 
glycine and proline-rich N-terminal PreLIM region (Figure 6). There is a high degree of 
sequence homology within the LIM region of all the six proteins (Schmeichel and 
Beckerle 1997). Additionally, all members of the family possess a nuclear export signal 
(NES) in their Pre LIM domains, assisting in shuttling from the nucleus to cytoplasm 
(Figure 6) (Nix and Beckerle 1997). This characteristic makes them excellent candidates 
during signal transduction, where extracellular signal needs to be transported to the 
nucleus to affect cellular activity. Zyxin family proteins localize to sites of focal 
adhesion, interact with the actin cytoskeleton, and take part in cell motility (Wang and 
Gilmore 2003). There is evidence that these proteins do not directly bind to DNA, but 
they can translocate into the nucleus, effecting cellular functions. They are able to bind 
transcription factors and other nuclear proteins (Petit, Fradelizi et al. 2000, Wang and 
Gilmore 2003)  
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FIGURE 6: GENERAL STRUCTURE OF ZYXIN FAMILY OF PROTEINS 
The proteins belonging to this family are characterized by presence of three LIM domains 
at the C-terminal and also have a proline rich non-homologous N-terminal PreLIM region 
containing the nuclear export signal (NES). 
 
Role of Zyxin family in DDR 
My lab has previously found that Zyxin family proteins, namely LPP and TRIP6 are 
detected at telomeres and interact with shelterin proteins. Yeast two hybrid assay showed 
an interaction between C-terminal of LIM protein TRIP6 with OB-fold-containing 
shelterin protein POT1. Depletion of LPP and TRIP6 proteins in human cells led to DDR 
response, suggesting a possible role of the Zyxin family proteins in preventing DDRs in 
cells (Sheppard and Loayza 2010, Sheppard, Savinova et al. 2011). 
Zyxin family subset proteins share a great degree of similarity in structure. This suggests 
that they might act co-operatively or compensate for each other’s activity in executing a 
particular cell function. For example, closely related proteins LPP and TRIP6 are found 
to interact with Shelterin complex and prevent unscheduled DDR at telomeres (Sheppard 
and Loayza 2010). This redundancy in function implies that LPP and TRIP6 either act in 
synchrony as partners and/or are able to compensate the necessary role in inhibition of 
DDR in cells.  
LIM NES  LIM  LIM 
Pre‐LIM region  LIM region 
N‐  ‐C Proline rich 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Ajuba LIM protein 
Ajuba belongs to the third category of LIM proteins and is most distantly related to LIM 
proteins LPP, TRIP6, Zyxin from the Zyxin family. Ajuba has 538 amino acids and 
molecular weight is approximately 55kD. It contains three LIM domains at the C-
terminus and a proline rich Pre-LIM region. Tissue expression of Ajuba showed that 
Ajuba was expressed in all embryonic germ layers and the expression is reduced in 
maturing embryos. In adult tissues, Ajuba is expressed in skin, brain, kidney and 
genitourinary organs (Goyal, Lin et al. 1999).  
Immunofluorescence analysis in embryonal carcinoma cells revealed that Ajuba was 
localized to cell-cell contacts (Kanungo, Pratt et al. 2000). In epithelial cells, Ajuba is 
recruited to cell-cell junctions by virtue of the LIM region interacting with α-catenin 
bound to the cytoplasmic tail of E-cadherin and the PreLIM region binding directly with 
F-actin (Marie, Pratt et al. 2003).  
Ajuba has a functional nuclear export signal (NES) in the Pre-LIM regions. Subcellular 
localization of exogenously expressed Ajuba in NIH 3T3 cells revealed that the full 
length protein and the pre-LIM region are mainly localized in the cytoplasm, while the 
truncated Ajuba containing just the C-terminal 3 LIM domains localized in the nucleus 
(Goyal, Lin et al. 1999). Later, it was shown that Ajuba was able to enter the nucleus and 
the LIM domains were necessary for this localization. Accumulation of the LIM domains 
of Ajuba in the nucleus of embryo-derived teratocarcinoma (P19) cells in mice resulted in 
growth inhibition and spontaneous endodermal differentiation (Kanungo, Pratt et al. 
2000). However, the exact mechanism of Ajuba recruitment and localization to the 
different cellular compartments needs to be further investigated.  
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Studies have indicated that Ajuba is unable to bind to DNA directly, but its translocation 
to the nucleus has an effect on transcription. Ajuba interact with Snail, a transcription 
repressor through LIM region and helps recruit protein arginine methyltransferase-5 
(Prmt5) to the promoter region of E-cadherin gene to silence it (Ayyanathan, Peng et al. 
2007, Hou, Peng et al. 2008). Thus, Ajuba might serve as a communicator between cell 
surface signaling and nuclear response by helping in assembly of multi protein 
complexes. 
Ajuba has also been implicated in the regulation of different signaling pathways. The 
PreLIM region of Ajuba has been shown to interact with the SH3 domains of Grb2 
(Growth factor receptor-bound protein 2), an adapter protein that provides a critical link 
between cell surface growth factor receptors and the Ras signaling pathway. The 
interaction of Ajuba with Grb2 led to increased MAP kinase activity in fibroblasts. Upon 
expression of murine Ajuba in Xenopus oocytes, meiotic maturation takes place in a 
Grb2- and Ras-dependent manner (Goyal, Lin et al. 1999). Interaction assays showed that 
Ajuba binds to the atypical protein kinase C (aPKC) scaffold protein p62 and is involved 
in modulating the IL-1-induced NF-κB activation by impacting the assembly and activity 
of the atypical PKC/p62/TRAF6 multiprotein signalling complex (Feng and Longmore 
2005).  
Ajuba is a protein that participates in various cellular functions. This versatility of Ajuba 
can be attributed to its ability to translocate to various subcellular compartments and 
interact with different binding partners to form complexes that are required for critical 
cell processes. 
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OBJECTIVE OF THE THESIS  
The ability of Zyxin family members to shuttle between nucleus and cytoplasm and their 
ability to form multiprotein complexes make then interesting partners in cell signaling 
and transduction pathways. Previous research from our laboratory show that some 
members from the Zyxin family participate in preventing unwanted DDR in cells. My 
thesis explores whether Ajuba, another Zyxin family member, has an overlapping role in 
preventing unscheduled DDR in human cells. Primarily, we investigate if Ajuba 
participates in DDR inhibition. We show that Ajuba depletion in cancer cells causes 
induction of DNA damage, decrease in cell proliferation and an accumulation of cells in 
S phase. Then, we detect the type of signaling pathway Ajuba partakes in and identify 
that Ajuba represses ATR mediated DNA damage response. We further explore if the 
phenotype is specific to cancer cells or is also observed in normal fibroblasts. We detect 
that Ajuba participates upstream in the ATR kinase pathway through its association with 
RPA. Ajuba plays an essential role in cell viability and helps repress inappropriate 
activation of DNA damage response in cells (Figure 7). Even though Zyxin family 
members seem to have redundant roles in repressing undesirable DDR in cells, LIM 
protein Ajuba seem to have evolved as a large scale repressor of DDR, while LPP and 
TRIP6 roles are restricted to specific locations such as telomeres.  
. 
 
 
 
  21 
 
FIGURE 7: A MODEL DEPICTING ROLE OF AJUBA IN REPRESSING DNA 
DAMAGE RESPONSE.  
During normal replication Ajuba remains associated with RPA and prevents ATR from 
interacting with RPA complex and hence prevents ATR activation. During replication 
stress, the association between Ajuba and RPA is greatly reduced and thus ATR interacts 
with RPA causing ATR activation and phosphorylation of Chk1 kinase. Activated Chk1 
kinase impacts effector proteins leading to cell cycle delay, DNA repair and Apoptosis. 
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CHAPTER 2: MATERIALS AND METHODS 
CELL LINES AND ANTIBODIES 
HTC75 and IMR90 cells were used. HTC75 is a sub clone of HT1080, a fibrosarcoma 
cells line.  IMR90, a normal fibroblast cells was obtained from ATCC at population 
doubling 21. HTC75 cells were cultured in 10% BCS containing DMEM with 1% 
penicillin and streptomycin. IMR90 cells were cultured in 15% FBS containing DMEM 
with 1% penicillin and streptomycin. The Ajuba antibody (AB64451) and RPA-p-T21 
antibody (AB109394) was obtained from Abcam. The Ajuba serum was produced by 
immunization of rabbit against a peptide conjugated to KLH as per the protocol set by the 
manufacturer (BioSynthesis, Lewisville, TX).  The peptide was: NH2-
CPRGATGGPGDEPLEPAREQGSLDA-OH for Ajuba. The antibodies from Rb-
pS807/811 (9308), PARP (9542), p53-p-Ser20 (9287), Cyclin A2 (4656), Chk1-p-S345 
(2348), Chk1-p-S296 (2349) were obtained from Cell signaling. The Chk1 antibody was 
purchased from Sigma-Aldrich (C9358). The p53 antibody was acquired from Millipore 
(04-1083). The GAPDH antibody was obtained from Santa Cruz (sc-32233). The p53BP1 
(NB100-304) and RPA2 (9A1) antibody was purchased from Novus.  
RNA INTERFERENCE USING siRNA 
HTC75 cells and IMR90 cells were grown in DMEM with 10%BCS. Ajuba siRNA were 
synthesized by Dharmacon RNA Technologies. Double-stranded siRNA used were Ajuba 
si#1siRNA 5’-CCAAAUGGAUUGUGGAAGAUU-3’, Ajuba si#2 siRNA 5’-
GGGAAAGAGGUCAGAUUUAUU-3’ and Ajuba si#3 siRNA 5’-
GCAGCUGAGUGAUGAGGAAUU -3’. As a control, siRNA designed to target GFP 
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(Dharmacon) was used. The transfection was done using Lipofectamine (Invitrogen) 
according to the manufacturer’s instructions. Cells were grown to confluency of 
approximately 20-25% for 18-24 hr. prior to transfection. Transfection was done twice, 
once at 24hr and another at 48hr. The cells were collected for processing at 72hrs post 
transfection.  
IMMUNOPRECIPITATION 
Cell extracts and Immunoprecipitation were performed as described in (Loayza and de 
Lange, 2003, Nature, 424, 1013-8). 
IMMUNOFLUORENCE 
HTC75 cells and IMR90 cells were grown on glass coverslips. Cells were washed twice 
with PBS transfection period and fixed with 3% paraformaldehyde in PBS for 10 min at 
RT and then washed twice again with PBS followed by permeabilized in 0.5% NP-40 in 
PBS. This was followed by PBS washes and cells were blocked with PBG (PBS/0.2% 
fish gelatin. 0.5% BSA) for 30 minutes. Coverslips were then incubated with the rabbit 
anti-p53BP1 antibody at a concentration of 1:500 in PBG overnight. Cover slips were 
then rinsed three times with PBG solution and incubated with secondary TRITC-
conjugated goat anti-rabbit antibody (Jackson Immunoresearch) in PBG at a 
concentration of 1:500 for 45 min at RT. Cover slips were rinsed two times with PBG. 
Coverslips were then incubated with 4,6-diamidino-2-phenylindole (DAPI) at 100 ng/ml 
in PBG for 1 min to visualize the nuclei and mounted on to slides containing embedding 
media. Images were obtained with an Olympus BX61 fluorescence microscope using a 
60X objective connected to a Hamamatsu ORCA-ER CCD camera, controlled by the 
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SlideBook 5.1 image capture software. 
FLUORESCENCE ACTIVATED CELL SORTING (FACS) 
Transfected cells were rinsed twice in cold PBS/2mM EDTA, resuspended in 7 mL of 
PBS/2mM EDTA/2% Bovine serum albumin (BSA) and were fixed by drop wise 
addition of 3mL of cold 100% Ethanol and the cells were kept at 4°C for 24hr fixation. 
The cells were then spun down and resuspended in 0.5 ml of PBS/2 mM EDTA.10ul of 
heat inactivated RNase A (10 mg/ml). 25ul of Propidium Iodide (1mg/mL) were added, 
and the cells were incubated at 37°C for 30 minutes. The samples were then analyzed 
using a FACS Calibur Flow Cytometer.  
CHROMATIN ISOLATION 
To isolate chromatin, cells were resuspended (4 × 107cells/ml) in buffer A (10 mM 
HEPES, [pH 7.9], 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol, 1 mM 
DTT, protease inhibitors cocktail and 0.1 mM phenylmethylsulfonyl fluoride). Triton X-
100 (0.1%) was added, and the cells were incubated for 10 min on ice. Nuclei were 
collected in pellet 1 (P1) by low-speed centrifugation (4 min, 1,300 × g, 4°C). The 
supernatant (S1) was further clarified by high-speed centrifugation (15 min, 20,000 × g, 
4°C) to remove cell debris and insoluble aggregates. Nuclei were washed once in buffer 
A, and then lysed in buffer B (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, protease 
inhibitors as described above). Insoluble chromatin was collected by centrifugation (4 
min, 1,700 × g, 4°C), washed once in buffer B, and centrifuged again under the same 
conditions. The final chromatin pellet (P3) was treated with DNase (2U/ml) in DNase 
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buffer (NEB) for 10 mins and Laemmli buffer was added to all samples. (Modified from 
Mendez and Stillman, MCB 2001) 
CO-IMMUNPRECIPITATION TRAP ASSAY 
The TRAP assays were performed as per the manufacturer’s protocol (Millipore, S7710).  
A “Master Mix” was prepared using- 10X TRAP Reaction Buffer (5 µL), 50X dNTP Mix 
(1 µL), TS Primer (1 µL), TRAP Primer Mix (1 µL), Taq Polymerase (2 Units), dH2O 
(39.6 µL). Cell lysate was prepared as outlined in 2.3 (protein concentration range 10-750 
ng/µL). For the IP-TRAP assays, the immunprecipitations were performed as described 
above, and the beads were washed six times in lysis buffer.  The beads were then 
resuspended in 30µl of lysis buffer, and 2µl of the resuspended beads or total lysates 
were used as input for the assay. 2µl of lysis buffer was used in control tube. The tubes 
were placed the in the thermocycler block, and incubated at 30 ̊C for 30 minutes.  3-step 
PCR with 94 ̊C/30 seconds, 59 ̊C/30 seconds, and 72 ̊C /1 minute for 30-33 cycles in a 
thermocycler were carried out. 5 µL of loading dye containing bromophenol blue and 
xylene cyanol (0.25% each in 50% glycerol/50 mM EDTA) was added into each reaction 
tube. 25 µL of this was loaded and run on a 10% non-denaturing PAGE (no urea) in 0.5X 
TBE buffer.   
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CHAPTER 3: AJUBA PARTICIPATES IN REPRESSION OF 
ATR MEDIATED DNA DAMAGE RESPONSE  
 INTRODUCTION 
Our laboratory has previously identified that LIM proteins - TRIP6 and LPP play a role 
in preventing undesired DNA damage response (DDR). Depletion of these proteins in 
HTC75 cells leads to accumulation of DNA damage foci, specifically at mammalian 
telomeres. We further desired to investigate if other members of the Zyxin family also 
help in DDR repression. We selected another closely related Zyxin member called Ajuba 
and investigated its role in genomic stability.  
Eukaryotic cells have various signaling pathways to maintain genomic integrity. These 
pathways sense genotoxic stress and regulate cell cycle progression through DNA 
damage checkpoints. This provides an opportunity for cells to either repair the DNA and 
survive or undergo apoptosis. Several Cyclin/cdk complexes assist in cell cycle 
progression and are involved in phosphorylation of a specific set of target proteins. 
Retinoblastoma (pRb) protein phosphorylation is one such cyclin/cdk dependent 
phenomenon that allows cell cycle progression. pRb is hypophosphorylated in resting G0 
cells and gets increasingly phosphorylated during progression through G1 and is 
maintained in a hyperphosphorylated state until late mitosis. Cyclin types and levels vary 
according to the different cell cycle phases. For example, Cyclin E protein levels peak at 
the G1/S progression, followed by an increase in Cyclin A levels in the S phase. Thus, 
monitoring Cyclin expression can indicate cell cycle phase.  
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The replication checkpoint detects damage at replication forks and inhibits origin firing to 
stabilize the forks. Buildup of single stranded DNA at the forks leads to binding of RPA 
(Replication protein A). RPA2 can be phosphorylated in response to DNA damage at 
residues Thr21 and Ser33, by several members of PIKK family including checkpoint 
kinase ATR. This helps in the recruitment and activation of ATR and the phosphorylation 
of critical downstream kinases such as Chk1. Activation of Chk1 kinase stimulate several 
effector molecules such as p53 and Cdc25 phosphatases in this pathway, which can 
modulate proteins affecting cell cycle progression, DNA repair and apoptosis.   
Here, we deplete Ajuba using siRNA mediated gene silencing in HTC75, a human 
fibrosarcoma cell line and investigate its possible role in DNA damage response. The 
HTC75 cancer cell line is a subclone of HT1080 cells and is a fibrosarcoma cell line. 
We further examined IMR90 cells (normal human diploid fibroblasts), for the molecular 
effects observed in the HTC75 cells. The difference in the genetic makeup of cancer cells 
and normal (non-cancer) cells prompted us to study whether the effects of Ajuba 
depletion are limited to the cancer phenotype or whether the effects can also be viewed in 
normal untransformed cells. It is known that cancer cells show genomic instability as a 
result of accumulation of point mutations, deletions, chromosomal rearrangements and 
aneuploidy. Some of the mutations occur in genes involved in DNA repair programs such 
as excision, mismatch repair or in various DDR pathways such as ATM and ATR. This 
can lead to faulty DNA damage signaling system, uncontrolled cell cycle progression and 
greater sensitivity to DNA damaging drugs in cancer cell types.  
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At this point, by using siRNA mediated gene silencing, we investigate if Ajuba helps 
maintain genomic stability in cancer and non-cancer cell type. 
RESULTS 
Depletion of Ajuba in HTC75 cells causes decrease in cell number and cell cycle delay 
in S phase 
HTC75 cells were treated for 72 hours with 3 different siRNAs targeting 3 different sites 
in the Ajuba mRNA. siRNA for GFP was used as a negative control for the experiment. 
The decrease in protein levels was most effective for siRNA# 2 and 3 as seen in the 
immunoblot (Figure 8C). For all the 3 siRNAs used, there was approximately 50% 
decrease in cell count (Figure 8A) compared to siGFP treated cells. Additionally, the 
cells displayed changed morphology, similar to cells undergoing apoptosis with reduced 
cellular volume and retracted pseudopods (Figure 8B).  We subjected the cells to FACS 
analysis to determine if there was a delay in the cell cycle. We observed that there was a 
significant increase in S phase cells. Samples treated with siRNA 1, 2 and 3 had 42.3%, 
44.9% and 46.5% cells in S phase respectively (Figure 9A and Figure 9C). The GFP 
treated cells had only 24.95% cells in S phase. We also noted a minor but reproducible 
increase in cells in G2/M phase. We found that pRb was hyperphosphorylated and that 
Cyclin A2 levels were elevated in the Ajuba depleted cells, further conforming 
accumulation of cells in S phase (Figure 9B). We also observed in the FACS profile, an 
increase in sub-G1 DNA upon Ajuba depletion, indicating presence of dead cells (Figure 
9A). 
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FIGURE 8: DEPLETION OF AJUBA IN HTC75 CELLS RESULTS IN 
REDUCED CELL NUMBER.  
(A) Quantitation of the three independent siRNA experiments with cell counts performed 
72 hr after the first transfection. (B) Cells,72 hr after transfection, with GFP siRNAas 
controls. (C) Western blot showing the depletion of Ajuba using siRNA for three 
different target sites. 
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FIGURE 9: HTC75 CELLS DEPLETED FOR AJUBA SHOW S-PHASE DELAY.  
Attached and floating cells were processed 72h after siRNA transfection for (A) FACS 
sorting after PI staining. (B) Western blots for phosphorylated Rb and total levels of 
CyclinA2, with GAPDH as a loading control. (C) Cell cycle profiles of cells processed as 
in (A), with % of cells in S or G2/M indicated as averages of three independent 
experiments 
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Depletion of Ajuba in HTC75 cells causes Chk1 kinase activation and apoptosis  
Our results showed that depletion of Ajuba in HTC75 cells caused S phase delay and 
reduced cell count. Hence we wanted to investigate if Ajuba depleted cells experienced 
genotoxicity. We chose to detect the presence of 53BP1 protein, which is an early DNA 
damage sensor found to accumulate at sites of DNA damage. Accumulation of cells in S 
phase upon Ajuba depletion suggested that cells are under replication stress. Research 
shows that replicative stress activates ATR kinase in cells. Therefore, we decided to 
check for ATR activation by monitoring Chk1 phosphorylation and predicted that the 
pause in cell cycle might be due to stimulation of DDR in cells. We found that Ajuba 
depletion caused accumulation of p53BP1foci in the nuclei compared to the control cells 
treated with GFP siRNA (Figure 10A). The control siRNA showed 2% cells containing 
five p53BP1foci per nuclei, with an increase in these foci to 37% in the Ajuba siRNA 
treated cells (Figure 10B). There is an average of 1-2 foci per cell in HTC75 cells; this 
represents the background damage level in these cells. We detected phosphorylation of 
Chk1 kinase at residues Ser-296 and Ser-245 that are both ATR dependent sites (Figure 
10C). We also detected weak activation of p53 through phosphorylation at Ser-20 residue 
(Figure 10D).  Robust activation of DDR in cells prompted us to probe for cell death by 
apoptosis in Ajuba depleted cells. We probed for Poly (ADP-ribose) polymerase (PARP), 
an enzyme that is cleaved by caspase 3 during apoptosis and observed that PARP was 
indeed cleaved significantly in siRNA#3 treated cells (Figure 11A). We also tried to 
detect dead cells using trypan blue staining and saw an increase in trypan blue stained 
cells in all Ajuba siRNAs samples. siRNA#1 and siRNA#2  had approximately 18% dead 
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cells and siRNA#3 had 30% dead cells. Most dead cells were seen in siRNA#3, with only 
7% dead cells in the control siRNA (Figure11B). 
 
FIGURE 10: DEPLETION OF AJUBA RESULTS IN ACTIVATION OF THE 
DNA DAMAGE RESPONSE IN HTC75 CELLS. 
(A) Immunofluorescence using p53BP1 antibody on cells fixed 72 hr. after transfection 
with siRNA #3, and siGFP as a negative control. (B) Quantitation of the number of 
p53BP1 foci on three independent siRNA experiments. (C, D) Western blots for 
induction of Chk1phosphorylation (C) and induction of p53 (D) after 72hrs transfection 
of Ajuba siRNA. 
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FIGURE 11: INDUCTION OF APOPTOSIS UPON AJUBA DEPLETION IN 
HTC75 CELLS. 
(A) Western blot probed for anti-PARP in Ajuba depleted cells, with GAPDH as loading 
control in lower panel. (B) Cell viability measured using trypan blue staining, 72 hr post 
siRNA transfection. 
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Depletion of Ajuba in IMR90 cells causes decrease in cell number and cell cycle delay 
in G2/M phase 
To investigate if the effects observed in HTC75 cancer cells are not restricted to cancer 
phenotype, we studied the effect on Ajuba depletion in IMR90, a normal diploid 
fibroblast cell line. We treated IMR90 cells with Ajuba siRNA#3 and confirmed 
depletion by immunoblotting (Figure 13A). Ajuba depleted cells had reduced number of 
cells, with approximately 40% decrease in cell count (Figure 12A & B). Using FACS 
analysis, a G2/M delay was detected when compared to the GFP siRNA treated control 
cells. The control GFP siRNA treated cells had 9.23% cells in G2/M phase compared to 
22.79% for the Ajuba siRNA treated cells (Figure 12C). We also observed an increase in 
Cyclin A level and a small increase in Rb hyperphosphorylation (Figure13C).  
Depletion of Ajuba in IMR90 cells causes Chk1 kinase activation and apoptosis 
The Ajuba depleted cells showed accumulation of p53BP1foci in the nuclei indicating 
DNA damage sites (Figure 12B). We also found phosphorylation of Chk1 kinase at Ser-
345 site, indicating activation of ATR kinase pathway. There was also low level of 
cleaved PARP in the Ajuba depleted cells denoting onset of Apoptosis (Figure 13D). 
 
 
 
 
 
  35 
FIGURE 12 
  
FIGURE 12: IMR90 CELLS DEPLETED FOR AJUBA HAS REDUCED CELL 
NUMBER AND G2/M DELAY.  
(A) Cell counts of IMR90 cells taken 72 hr after transfection of siRNA#3. (B) Picture of 
IMR90 cells for siRNA#3 taken 72 hr after transfection. (C) Cell cycle profiles of cells 
processed as in (B) with % of cells in G2/M indicated as averages of three independent 
experiments. 
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FIGURE 13 
 
FIGURE 13: IMR90 CELLS DEPLETED FOR AJUBA SHOW A DNA DAMAGE 
RESPONSE.  
(A, C, D) Western blots for Ajuba, Cyclin A, Rb, Chk1 phosphorylation, and PARP 
cleavage on lysates prepared from IMR90 cells 72 hr after transfection with siRNA#3. 
The loading controls with GAPDH for each blot are shown. (B) Staining for p53BP1 in 
Ajuba-depleted cells (siRNA#3), with siGFP as a control. 
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DISCUSSION 
The inability of the cells to multiply and accumulation of cells in S phase after Ajuba 
depletion indicates that the cells are experiencing replicative stress. These cells were not 
subjected to exogenous agents like UV radiation and DNA damaging chemicals, hence it 
can be inferred that the effect observed is caused by Ajuba depletion.  
53BP1 is a sensor of DNA lesions and helps in chromatin recruitment of various proteins 
required to elicit an efficient repair response. The 53BP1 foci detected on Ajuba 
depletion are representative of DDR triggered at sites of stalled replication forks, DNA 
crosslinks or misincorporated nucleotides. Thus, depletion of Ajuba unleashes a DNA 
damage response that is usually inactivated in normal unperturbed cells.  
Chk1 kinase is phosphorylated by activated ATR kinase. Phosphorylation of Chk1 kinase 
on ATR dependent sites after Ajuba depletion suggests that Ajuba participates in 
repression of ATR mediated DNA damage. Activated Chk1 kinase can phosphorylate 
p53 at Ser-20. Thus, weak phosphorylation of p53 at Ser-20 and apoptotic cell death 
observed, can be due to down-stream effects of activated Chk1 kinase. Overall, the 
results indicate that Ajuba is necessary for cell viability and the cellular effects detected 
upon Ajuba depletion are similar to the ones observed in cells experiencing replication 
stress.  Hence, we describe Ajuba as surveillance protein that keeps a check on 
unnecessary initiation of ATR mediated DNA damage response during normal S phase. 
Normal diploid fibroblasts like IMR90 have intact DNA surveillance mechanisms like 
check point kinases and DNA damage signaling pathways to halt proliferation to repair or 
induce cellular senescence or apoptosis.  HTC75 is a tumor cell type with constitutive 
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activation of Ras oncogene leading to a phenotype of fibrosarcoma. Both cell types 
showed similar cellular effect of Ajuba depletion, implying a common role of Ajuba in 
these cells and not just an acquired phenotype of cancer cells. However, there was a 
difference in the type of cell cycle delay observed. We detected G2/M phase delay in 
IMR90 while HTC75 showed accumulation of cells in S phase. We believe that this 
could be due to cell type specific activation of different downstream targets of Chk1 such 
as Cdc25 phosphatases. HTC75 and IMR90 could activate different Chk1 effector 
molecules to generate a discrete cell cycle delay response. Human cells contain three 
isoforms of CDC25 phosphatases. Inhibition of Cdc25A is implicated in S and G2/M 
phase arrest in cells, while inhibition of Cdc25B and C isoforms lead to G2/M phase 
arrest (Xiao, Chen et al. 2003, Loffler, Rebacz et al. 2006, Thanasoula, Escandell et al. 
2012). Although, we have not addressed through experiments, as to which Chk1 targets 
are responsible for the specific cell cycle delay, we discover that both cell type show 
robust ATR activation and cell death by apoptosis.  
In conclusion, we represent Ajuba as an important protein required for cell survival and a 
repressor of unwanted ATR activation in both cancer and non-cancer cells.  
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CHAPTER 4: AJUBA ASSOCIATES WITH RPA IN 
UNPERTURBED HTC75 AND IMR90 CELLS 
INTRODUCTION 
An early event in the activation of ATR kinase pathway is phosphorylation of RPA. RPA 
is an OB (oligonucleotide/oligosaccharide binding) folds containing protein that binds to 
ssDNA and plays a role in both the DNA replication and the ATR kinase pathway. RPA 
is a heterotrimeric protein, with subunit RPA1 (RPA70) containing four OB folds, RPA2 
(RPA32) and RPA3 (RPA14) containing one OB fold. The N-terminal domain of RPA70 
directly interacts with several checkpoint proteins, including ATR (through ATRIP), 
Rad17-Replication Factor C (RFC), p53, and Rad9. RPA interaction with ATRIP and 
RAD9 helps recruit ATR and TOPBP1 to the DNA damage site. RPA phosphorylation is 
crucial for ATR activation. RPA32 can be phosphorylated by a variety of DNA damaging 
events such as exposure to UV irradiation, ionizing irradiation (IR), treatment with DNA-
damaging chemicals and use of DNA- polymerase inhibitors (hydroxyurea (HU) and 
aphidicolin). ATM, ATR and DNA-PK can phosphorylate Thr21 residue on RPA2, while 
Ser33 residue phosphorylation is mainly ATR dependent. 
In the earlier results we showed that reduction of Ajuba levels in cells caused an 
unscheduled activation of ATR kinase pathway indicating that Ajuba is a member of this 
pathway and helps normal progression of the S phase through ATR repression. The next 
step was to determine how Ajuba participates in the ATR pathway. To elucidate this, we 
examined different types of proteins previously known to interact with the Zyxin family 
members. Previous research from our lab has revealed that Zyxin family member, TRIP6, 
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interacts with an OB fold protein, POT1, at telomeres ands helps prevent DDR at 
telomeres. Both POT1 and RPA bind to ssDNA by virtue of their OB fold domains and 
both have implications in ATR mediated DDR. Since Ajuba is another Zyxin family 
member, we hypothesized that there might be an interaction between OB fold containing 
RPA and LIM protein Ajuba.  
Later, we decided to use Hydroxyurea (HU) treatment on cells to explore the interaction 
between Ajuba and RPA under replication stress. HU is widely known to cause DNA 
damage and activate ATR mediated DNA damage in the cells. HU is an inhibitor of 
ribonucleotide reductase (RNR) activity, which is a rate-limiting enzyme for DNA 
synthesis. RNR reduces ribonucleotides to deoxyribonucleotides and is the source for 
deoxynucleotides in cells. Inhibition of RNR leads to decrease in the concentration of the 
dNTP pool, stalling of replication forks, accumulation of ssDNA and cell cycle arrest in 
G1/S phase. 
RESULTS 
RPA32 is phosphorylated upon Ajuba depletion and RPA associates with Ajuba in 
HTC75 and IMR90 cells 
We carried out Immunoprecipitation of Ajuba using commercially available antibody and 
serum, and probed for the presence of RPA32 subunit in the pull down. We observed the 
presence of RPA32 upon Ajuba immunoprecipitation in both HTC75 and IMR90 cells 
(Figure 14A). This suggests an interaction between RPA32 and Ajuba in these cell lines. 
RPA phosphorylation occurs early in the ATR kinase pathway, and a significant increase 
in RPA32 phosphorylation at Thr21 was detected in Ajuba depleted cells (Figure14B). 
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FIGURE 14: AJUBA ASSOCIATES WITH RPA IN HTC75 AND IMR90 CELLS.  
(A) Western blot probed with a total anti-RPA32 antibody after Immunoprecipitation 
with a commercial anti-Ajuba antibody (com.) or anti-peptide serum from IMR90 or 
HTC75 extracts as indicated. Left panel: total lysates (input) for each cell line, and the 
pre-immune serum (PI) used as a control for the Immunoprecipitation. (B) Westernblot 
for RPA32-p-Thr21 in both HTC75 and IMR90 Ajuba-depleted cells. A non-specific 
band is marked by a (*). Total RPA32 Levels are shown at the bottom. (C) Model for the 
role of Ajuba in repression of ATR. The “?” indicates that the interaction between Ajuba 
and RPA could be direct or indirect. See text for details.  
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RPA and Ajuba interaction is present during replication but is lost upon ATR 
activation. 
HTC75 cells were exposed to 2mM HU for 3, 6 and 24 hrs. Activation of ATR kinase 
was confirmed using immunoblotting with antibody against RPA Thr21. Increase in time 
exposure to 2mM HU progressively increased phosphorylation of RPA at Thr21, with 
most phosphorylation observed after 24hrs exposure (Figure 15A). Immunoprecipitation 
using Ajuba antibody was carried out in the cell lysates and RPA32 was detected in the 
untreated and 3hr HU exposed cells, but not in 6hr and 24hr HU treated cells (Figure 
15B). This suggests that the interaction of RPA with Ajuba is diminished on increasing 
time exposure to HU.  
HU treatment blocks replication and causes ATR activation, hence we were interested to 
test if the binding is affected only upon ATR activation or also during normal replication 
in cells. HTC75 and IMR90 cells were subjected to double thymidine block and released 
in S phase. Another set of cells was treated with HU for 24hrs and untreated cells were 
used as control. FACS analysis was carried out to confirm cell cycle profile in both cell 
types. In unsynchronized cells most cells were in G1 phase. On HU treatment, G1/S 
phase arrest was observed and the double thymidine block released most cells in S phase 
(Figure 16A). Immunoprecipitation was carried out with commercial Ajuba antibody and 
the presence of RPA32 subunit in the pull downs was detected by immunoblotting.  We 
observed that RPA32 could be immunoprecipitated in S phase cells and untreated control 
cells, but not in the pull down of HU treated cells (Figure15A). Both cell types showed 
presence of RPA70 subunit (containing 4 OB folds) in the Ajuba antibody pull-down. 
RPA70 was detected in untreated cells but not in HU exposed cells (Figure 16B). In 
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general, the data suggests that there was loss of interaction between RPA and Ajuba upon 
ATR activation but not during replication.  
A 
 
B  
   
FIGURE 15: AJUBA LOSES ITS INTERACTION WITH RPA AFTER ATR 
ACTIVATION IN HTC75 CELLS 
(A) Westernblot for HTC75 cells indicating RPA32-P-Thr21 in untreated (UT) cells and 
cells exposed to 2mM HU for 3, 6 and 24hr. A non-specific band is marked by a (*).       
(B) Westernblot probed with a total RPA32 antibody (top panel) after 
immunoprecipitation with a commercial anti-Ajuba antibody in HTC75 extracts in 
untreated (UT) and cells exposed to 2mM HU at indicated time points. Total RPA32 in 
lysate (inputs) are indicated on top left. Total RPA32-P-Thr21 and Ajuba in cell lysates 
are indicated. GAPDH is used as loading control. 
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FIGURE 16: AJUBA LOSES ASSOCIATION WITH RPA UPON ATR 
ACTIVATION BUT NOT DURING DNA REPLICATION 
(A) Western blot probed with a total RPA32 antibody after Ajuba immunoprecipitaion in 
HTC75 (top panel) and IMR90 (bottom panel) extracts in untreated (UT) cells, cells 
exposed to 2mM HU and double thymidine treated cells released in S phase. Immunoblot 
with GAPDH antibody is used as loading control. FACS analysis of cells shown in right 
panel (B) Western blot probed with a total RPA70 antibody after immunoprecipitaion 
with anti-Ajuba antibody in HTC75 cells. 
 
!HTC75!cells!
IMR90!cells!
GAPDH!
GAPDH!
RPA32!
RPA32!
Un
tre
ate
d!
IP!Ajuba!
24
!hr
!
2m
M
!H
U!
UT
! D
OU
BL
E!
TH
YM
ID
IN
E!
!!(S
Jph
as
e)!24
!hr
!
2m
M
!H
U!
DO
UB
LE
!
TH
YM
ID
IN
E!
!!(S
Jp
ha
se
)! HTC75! !UT! 24hr!
HU!!
dT!
2hr!
G1# 64%# 58.85%# 22.1%#
S# 24%# 41.14%# 76.7%#
G2/M# 11%# 0%# 1.62%#
FACS#analysis#
IMR90! !UT! 24hr!
HU!!
dT!
4.5hr!
G1# 63%# 55.5%# 20%#
S# 8%# 44%# 73%#
G2/M# 29%# 0%# 4%#
FACS#analysis#
Be
ad
s!
!on
ly!
Un
tre
ate
d!
IP!Ajuba!
24
!hr
!
2m
M
!H
U!
UT
! DO
UB
LE
!
TH
YM
ID
IN
E!
!!(S
Jph
as
e)!24
!hr
!
2m
M
!H
U!
DO
UB
LE
!
TH
YM
ID
IN
E!
!!(S
Jp
ha
se
)!
Be
ad
s!
!on
ly!
  45 
DISCUSSION 
The results indicate that Ajuba interacts with RPA and prevents its phosphorylation in 
cells unexposed to exogenous DNA damaging agents. This could be due to shielding of 
RPA32 by Ajuba, thereby preventing RPA phosphorylation and halting unnecessary ATR 
activation during a normal S phase as shown in the model (Figure 14C). Depletion of 
Ajuba might leave the phosphorylation sites on the unassociated RPA32 subunit 
unprotected and exposed. These sites can be recognized and phosphorylated by PIKKs 
such as ATR causing their unnecessary activation.  
My results also detect an interaction between RPA70 subunit and Ajuba. The N terminal 
RPA70 OB-fold domain interacts with Rad9 protein of the 9-1-1 complex. This 
interaction is important for RAD9 recruitment to sites of DNA damage and loading of 9-
1-1 complex on DNA, a critical step for ATR activation. Ajuba interaction with RPA70 
might prevent its association with Rad9, there by preventing assembly of the components 
required for ATR activation. It would be interesting to study if the interaction between 
RPA subunits and Ajuba is direct or mediated by other proteins. Also, it would be  
noteworthy to observe the importance of LIM domains in the interaction. Over all, the 
results portray that Ajuba might be a key player that participates upstream in ATR 
signaling pathway by associating with RPA and protects cells from unwanted ATR 
activation.   
Introduction of replication stress by HU in both cell types led to dissociation of Ajuba 
from RPA but the interaction was stable in asynchronous and normal replicating cells. 
Ajuba might protect RPA from unwanted phosphorylation during normal replication 
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cycle and restricts DDR to few sites of endogenous replication damage, mainly caused by 
DNA polymerase errors or oxidative stress. This allows cells to progress in the cell cycle. 
However, exposure to agents causing extensive DNA damage could cause the RPA-
Ajuba association to debilitate, probably by chemical modification of the proteins. 
However, the exact mechanism by which the association is disrupted needs further testing 
and experimentation. Overall, the results suggest that Ajuba could be a repressor 
molecule that remains associated with RPA during normal S phase but loses its 
association upon extensive DNA damage causing global activation of ATR signaling in 
cells.  
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CHAPTER 5: POTENTIAL ROLE OF AJUBA AT 
TELOMERES 
INTRODUCTION 
Subcellular localization of exogenously expressed Ajuba in NIH 3T3 mouse embryo 
fibroblasts revealed that the full length protein and the pre-LIM region are mainly 
localized in the cytoplasm, while truncated Ajuba containing just the C-terminal 3 LIM 
domains is localized in the nucleus. Ajuba has a functional nuclear export signal (NES) in 
the pre-LIM regions. Studies have indicated that Ajuba is unable to bind to DNA directly, 
but its interaction with other proteins has an effect on its cellular localization. Ajuba 
mainly localizes in cytoplasm but it can translocate to the nucleus to affect cell processes 
such as transcription and cell differentiation (Goyal, Lin et al. 1999, Kanungo, Pratt et al. 
2000). However, the exact mechanism of Ajuba localization and recruitment to chromatin 
needs to be investigated.  
According to the model depicted in figure 14C, we expect an association between Ajuba 
and RPA to occur on the chromatin during normal replication process, with an expected 
reduction in the association upon massive DNA damage. Hence, we planned to carry out 
subcellular fractionation to detect presence of Ajuba on chromatin. According to our 
model, we would expect reduced amount of Ajuba in the chromatin fraction upon DDR 
activation as compared to the unperturbed cells.  Also we would speculate a loss of 
interaction between the ssDNA bound RPA and Ajuba on global activation of ATR. 
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Then we were interested in uncovering protein interactions that might help Ajuba 
associate with chromatin. Thus, we tried to detect if Ajuba associates with POT1, which 
is a ssDNA binding protein containing OB folds like RPA. POT1 is the only protein from 
the Shelterin complex that binds to the ssDNA telomeric overhang directly due to the 
presence of two N- terminal OB folds. The Shelterin complex on the telomere has TRF1 
and TRF2, which bind double stranded DNA directly through a MYB-type DNA binding 
domain. TIN2 has the ability to interact with both TRF1 and TRF2 simultaneously to 
recruits TPP1/POT1 to the complex. TPP1 recruits POT1 and also has a recruitment 
domain for telomerase, thus providing a link between the enzyme and telomeres (de 
Lange 2005). The Shelterin complex is known to have a negative effect on the action of 
telomerase, a reverse transcriptase enzyme, that helps to stabilize telomere length in 
human stem cells, reproductive cells and cancer cells by adding TTAGGG repeats onto 
the telomeres using its intrinsic RNA as a template for reverse transcription. The catalytic 
core of human telomerase is composed of two subunits: the human telomerase reverse 
transcriptase (hTERT) and the human telomerase RNA component (hTR). Telomerase 
activity has been found in most human tumors but not in adjacent normal cells and hence 
telomerase activation might constitute an additional step in promoting oncogenesis. 
POT1 plays a crucial role in cis-inhibition of telomerase as it binds to the 3’ overhang, 
which is the substrate for telomerase. Direct competition for overhang binding between 
POT1 and telomerase was observed in in vitro studies (Loayza and De Lange 2003). 
However, in vitro studies now show that TPP1-POT1 dimer is capable of increasing the 
processivity of telomerase (Wang, Podell et al. 2007). The OB fold domain of TPP1 has 
been shown to interact directly with telomerase. One study also identifies that TIN2 
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binding to TPP1 might help in telomerase recruitment (Abreu, Aritonovska et al. 2010). 
These studies shed light on duality in the regulation of telomerase by Shelterin complex.  
Depletion of POT1 in mouse cells results in the accumulation of DNA damage sensor 
proteins such as p53BP1 and γH2AX collectively called TIFs, (telomere dysfunction-
induced foci) and POT1 inhibits the unscheduled activation of checkpoint kinase ATR at 
telomeres. Along with preventing DDR, POT1 also participates in telomere length 
maintenance. The N-terminal truncation in the DNA binding OB folds leads to extensive 
telomere elongation (Loayza and De Lange 2003). 
Initially, we determine if Ajuba localizes to chromatin and then we explore if Ajuba 
interacts with POT1 in cells and assists POT1 with its telomeric function.  
RESULTS 
A probable isoform of Ajuba is observed in chromatin fraction in HTC75 cells 
Subcellular fractionation was carried out to observe chromatin association of Ajuba. The 
cytoplasmic and chromatin separation was confirmed using antibodies for alpha-tubulin 
for cytoplasmic and histone 3 for chromatin fractions. The fractions were subjected to 
immunoblotting to detect Ajuba using commercially available antibody. Full length 
Ajuba has an expected molecular weight around 55kD and this band was observed in the 
cytoplasmic fraction and total lysate only. Another band whose molecular weight was 
less than 55kD was detected in the nuclear and chromatin bound fractions in untreated 
cells. There was absence of full-length Ajuba band in these fractions. Human cells have 
three isoforms of Ajuba. Based on the molecular weight (approx. 40kD), we speculate 
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that the low molecular weight band could be isoform 3 of Ajuba, found in humans.  A 
similar band was also detected in the total cell lysate with Ajuba antibody along with the 
full length Ajuba after 24hr HU treatment of cells. This predicted isoform was not present 
in the nuclear and chromatin bound fractions, however was now detected in cytoplasmic 
fraction (Figure 17).  
 
 
FIGURE 17: CELL FRACTIONATION TO DETERMINE AJUBA 
LOCALIZATION IN HTC75 CELLS 
Cell fractionation was carried out in 2mM HU treated cells (right panel) and untreated 
HTC75 cells (left panel). Immunoblots indicate the presence of Ajuba, α-Tubulin and 
Histone 3 in the indicated cell fractions.  “?” Indicates probable isoform.  
CP- Cytoplasmic fraction, NP- Nucleoplasmic fraction, CB- Chromatin bound fraction 
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Ajuba interacts with POT1 in HTC75 cells  
We then sought to investigate a possible interaction between Ajuba and POT1 and also its 
binding partner TPP1. Immunoprecipitation with Ajuba antibody in HTC75 cell lines 
expressing either MYC-POT1, MYC-TPP1 revealed that Ajuba antibody could pulldown 
MYC-POT1 but not MYC-TPP1, suggesting an interaction between POT1 and Ajuba in 
the cell lysates (Figure 18A). We also tried to deduce if Ajuba associates with double 
stranded telomere binding proteins-TRF1 and TRF2. Ajuba immunoprecipitation in 
FLAG-TRF1 expressing HTC75 cells did not show presence of TRF1 in the pulldown 
(Figure 18B). TRF2 was also not detected in the Ajuba pulldown in HTC75 cells (Figure 
18C). HTC75 cells expressing MYC-Vector and FLAG-Vector were used as controls. 
This suggests that Ajuba interacts specifically with POT1 in the cells.   
We further wanted to detect if the interaction is dependent on the OB folds of POT1. We 
used HTC75 cells expressing N terminal truncated POT1 that lacked one and a half OB 
folds called ΔOB and a full length MYC-POT1 (Figure 19A). MYC-TPP1 was used as a 
control. We observed that full length MYC-POT1 was detected in Ajuba IP but not in the 
ΔOB POT1 suggesting that the Ajuba -POT1 interaction was lost in the ΔOB POT1 cell 
line (Figure 19B).  
Ajuba is detected at telomeres in HTC75 cells 
Association of Ajuba with POT1 prompted us to inspect if Ajuba is detected at telomeres. 
We carried out chromatin immunoprecipitation to investigate this. TRF1 antibody 
pulldown was used as a positive control. Immunoprecipitation with Ajuba antibody 
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revealed that Ajuba signal was detected at telomeric repeats in HTC75 cells, indicating an 
association between Ajuba and human telomeres (Figure 19C).  
To investigate if Ajuba assists POT1 in preventing DDR at telomeres, we carried our Co-
immunofluorence using antibody against 53BP1 and TRF1 (denoting telomeres) in Ajuba 
depleted cells. Though we noticed an increase in 53BP1 foci in Ajuba depleted cells, very 
less foci were seen to co-localize with TRF1 (date not shown) The control GFP siRNA 
showed 2% cells with five p53BP1foci per nuclei, with an increase in the cells to 37% in 
Ajuba siRNA treated cells (Figure 10B).  
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FIGURE 18: AJUBA CO-IMMUNOPRECIPITATES WITH POT1  
(A) Immunoblotting on lysates made from HTC75 cells obtained through retroviral 
transduction, stably expressing MYC‐POT1 and MYC-TPP1 (Vector only control is 
shown in left lane). The lysates were used for immunoprecipitations with Ajuba antibody 
and analyzed for the amounts of MYC‐POT1 and MYC-TPP1 by Westernblot with the 
9E10 antibody. The total fraction was run alongside as indicated. (B) Same as (A), with 
FLAG-TRF1 expressing HTC75 cells. (C) Westernblot with TRF2 antibody after 
immunoprecipitaion with Ajuba antibody in HTC75 cells.  
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FIGURE 19: AJUBA INTERACTS WITH OB FOLDS OF POT1 AND IS 
DETECTED AT HUMAN TELOMERES.  
(A) Domain structure of full length human POT1 with TPP1 binding region on C-
terminus and two predicted OB folds on N-terminus. ΔOB POT1, with one and half OB 
folds deleted shown on right. (B) Immunoblotting on lysates made from HTC75 cells 
obtained through retroviral transduction, stably expressing MYC‐POT1, MYC- POT1 
ΔOB and MYC-TPP1 (Vector only control is shown in the left lane). The lysates were 
used for immunoprecipitation with Ajuba antibody and analyzed by Westernblot with the 
MYC antibody. The total lysate fraction was run alongside as indicated. (C) Chromatin 
immunoprecipitation in HTC75 cell lysate with antibodies listed on top (I=Immune, 
PI=PreImmune), and the total DNA fraction is on the left side of each blot as indicated. 
Extracted DNA samples were dot‐blotted on Nitrocellulose membrane, and probed with 
a TTAGGG probe for telomeres (top), or with an Alu probe (bottom) as a control. 
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Our data here depicts that Ajuba associates with telomeres by interacting with POT1. 
Since the protein did not seem to take part in preventing DDR specifically at telomeres, 
we hypothesized that Ajuba localization at telomeres might assist POT1 in its other 
function of telomere length maintenance through interaction with telomerase.  
Ajuba associates with telomerase in cancer cells 
To find if Ajuba interacts with telomerase, we carried out a Co-immunoprecipitation (Co-
IP) in cells exogenously expressing protein component of telomerase (hTERT).  HTC75 
cells expressing MYC-hTERT were used and IP carried out with Ajuba antibody. MYC-
hTERT was detected in the pulldowns suggesting a link between telomerase and Ajuba. 
We also treated the lysates with 50 ug/ml Ethidium bromide (EtBr) to disrupt DNA 
protein interactions and saw that MYC-hTERT was pulled down after the treatment as 
well (Figure 20A). 
Co-immunoprecipitation Telomeric Repeat Amplification Protocol (Co-IP TRAP) assay 
was carried out to further confirm if Ajuba is able to pull down active telomerase in HeLa 
II cell lysates (Figure 20B). HeLa II cells are telomerase positive cells. Antibody 
pulldowns with telomerase and FEN1, a protein known to interact with Telomerase were 
used as a positive control. We observed high molecular weight bands indicative of 
telomerase activity in the total lysates as well as in the pulldowns with telomerase, FEN1 
and Ajuba antibody. The lysate and the pulldowns were treated with RNase to abolish 
enzyme activity through degradation of telomerase RNA component. Thus, indicating 
that the high molecular weight repeats observed are due to telomerase activity. 
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Accordingly, the assay indicates that Ajuba antibody pulled down active telomerase in 
cell lysates (Figure 20C). 
A 
  
B   
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FIGURE 20: AJUBA INTERACTS WITH TELOMERASE.  
(A) Immunoblotting on lysates from HTC75 cells, obtained through retroviral 
transduction, stably expressing MYC-hTERT (Vector only control is shown in the left 
lane). The lysates were treated with and without 50 ug/ml Ethidium bromide (EtBr), as 
indicated. Immunoprecipitation with Ajuba antibody was carried out and analyzed for the 
amounts of MYC-hTERT by Western blot with the MYC antibody. The total fraction was 
run alongside as indicated. (B) The methodology utilized in the Telomeric Repeat 
Amplification Protocol (TRAP). In the first step of the reaction, telomerase adds a 
number of telomeric repeats (GGTTAG) onto the 3' end of a substrate oligonucleotide 
(TS). In the second step, the extended products are amplified by PCR using the TS and 
RP (reverse) primers, generating a ladder of products with 6 base increments starting at 
50 nucleotides: 50, 56, 62, 68, etc. (C) Co-immunoprecipitation TRAP assays showing 
the precipitation of telomerase activity with hTERT, FEN1 and Ajuba antibodies in HeLa 
II cell lysates. The high molecular weight bands above the internal control band represent 
telomerase activity. RNase was added to the IPs and cell lysate to abolish telomerase 
activity. Internal control (36bp) band is seen in all the lanes. Non-specific band is 
indicated by  *. 
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FIGURE 18: AJUBA INTERACTS WITH TELOMERASE.  
(A) Immunoblotting on lysates from HTC75 cells, obtained through retroviral 
transduction, stably expressing MYC-hTERT (Vector only control is shown in the left 
lane). The lysates were treated with and without 50 ug/ml Ethidium bromide (EtBr), as 
indicated. Immunoprecipitation with Ajuba antibody was carried out and analyzed for the 
amounts of MYC-hTERT by Western blot with the MYC antibody. The total fraction was 
run alongside as ind at d. (B) The method logy utiliz d in the Telomeric Repeat 
Amplification Pr tocol (TRAP). In the first step of the reaction, telomerase adds a 
number of telomeric repeats (GGTTAG) onto the 3' end of a substrate oligonucleotide 
(TS). In the second step, the extended products are amplified by PCR using the TS and 
RP (reverse) primers, generating a ladder of products with 6 base increments starting at 
50 nucleotides: 50, 56, 62, 68, etc. (C) Co-immunoprecipitation TRAP assays showing 
the precipitation of telomerase activity with hTERT, FEN1 and Ajuba antibodies in HeLa 
II cell lysates. RNase was added to th  IPs and cell lysat  to abolish tel merase activity. 
Internal co rol (36bp) band is seen in all th  la es. Non-specific band is indic te  by  *. 
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DISCUSSION 
Based on previous literature, there is evidence that Ajuba is unable to bind to DNA 
directly, but can translocate to the nucleus and associate with chromatin through 
interaction with other proteins. In humans, Ajuba has three known isoforms. Isoform 1 is 
full length, being the longest with 538 amino acids. Isoform 2 is composed of only 121aa, 
and has one LIM domain. This variant differs in the 5' UTR, lacks a portion of the 5' 
coding region, and initiates translation at a downstream in-frame start codon, compared to 
variant 1. Isoform 3 mRNA lacks multiple 3' coding exons and contains an alternate 3' 
terminal exon, resulting in a different 3' coding region and 3' UTR, compared to variant 
1.  Isoform 3 has 369 amino acids and is slightly shorter than isoform 1 but has a distinct 
C-terminus, with an expected molecular weight of 40kD. Isoform 3 contains no predicted 
LIM domains. The role and localization of isoforms 2 and 3 are mostly unknown. 
Based on the results, the band observed corresponds to the molecular weight of isoform 3 
and so it is appealing to assume that isoform 3 of Ajuba might be localized to chromatin 
fraction in cells and moves out to cytoplasm upon extensive DNA damage. Isoform 3 
does not have conserved LIM domains, but has the pre-LIM region and a distinct C- 
terminus probably conferring it a discrete role in cells. LIM proteins are known to change 
their localization upon interaction with a binding partner, hence we would like to 
hypothesize that such interaction might also influence Ajuba localization in cell, for 
example RPA and POT1 might have an impact on Ajuba localization. However, 
substantial amount of research is necessary to study how Ajuba translocates and 
associates with chromatin. Also, it is possible that full length Ajuba exists on chromatin, 
but the level was undetectable by Westernblotting.  Nevertheless, the correct identity of 
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the observed band needs to be confirmed. Transient transfection with tagged Ajuba 
isoforms need to be carried out to determine their cellular localization. 
Our results here further portray that LIM protein Ajuba interacts with OB fold proteins 
like RPA and POT1. We also show that Ajuba and POT1 interaction is dependent upon 
the OB fold region of POT1. This sheds light on the importance of OB folds in docking 
of LIM proteins and assisting the complexes to implement their biological role. It was 
also interesting to discover Ajuba at telomeres and its association with POT1, with no 
interaction observed with other shelterin proteins. This suggests that Ajuba binds to 
telomeres through POT1. We hypothesized that Ajuba might assist POT1 in preventing 
DDR at telomeres, however low amount of telomere induced foci (TIFs) were observed, 
with more foci in the rest of the nucleus suggesting that Ajuba has a genome wide role in 
DDR prevention rather than a localized one at telomeres. Another role of POT1 in cells is 
telomere length regulation and therefore we decided to explore if Ajuba was involved in 
telomere length regulation. 
Telomere maintenance is a complex event requiring a lot of proteins to act in 
coordination and may have several components yet to be detected. Proper telomere length 
regulation is essential for cell survival as it prevents premature cellular senescence and at 
the same time prevents cancer initiation. Shelterin proteins play a dual role of telomere 
end protection and telomere length maintenance. However, the exact mechanism by 
which shelterin proteins regulate telomerase action is not well understood. Shelterin 
complex has been viewed as a negative regulator of telomerase action, however literature 
also shows that some shelterin proteins help in telomerase recruitment. The results show 
that Ajuba associates with hTERT component of telomerase and can also pull down 
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active telomerase in whole cell lysates. The interaction of Ajuba with Shelterin protein 
POT1 as well as telomerase is suggestive of a possible role of Ajuba in telomere length 
maintenance. Further experiments are required to investigate if Ajuba actually affects 
telomere size. It would be interesting to see a change in the overhang and/or overall 
telomere length in Ajuba depleted and over-expressed cells. Over-expression of MYC 
tagged Ajuba in HTC75 cells was carried out using retrovirus mediated infection, 
however, the Ajuba transfected cells did not survive but the MYC vector expressing cells 
survived suggesting that Ajuba protein levels need to be maintained at a threshold level 
and that Ajuba depletion or overexpression disrupts the balance, affecting cell viability.  
Overall, the results suggest a possible role of Ajuba at human telomeres.  
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CONCLUDING REMARKS AND FUTURE DIRECTIONS 
In order to maintain genomic integrity, evolutionarily conserved cellular pathways have 
evolved in cells. These molecular pathways sense, respond and repair specific types of 
DNA damage and are intimately interconnected with the checkpoint systems. DDRs are 
highly coordinated and complex responses to extrinsic or intrinsic damage. However, 
DDRs need to be controlled and restricted during normal cellular events like replication 
and mitosis for cell cycle progression and cellular proliferation. Untimely activation of 
DDR in cells can lead to unnecessary halt in cell cycle and impel cells towards apoptosis 
or senescence.  
In this thesis, we describe LIM protein Ajuba as a repressor protein that inhibits 
unwanted DDR in cells by preventing the activation of ATR pathway. We show that 
Ajuba acts upstream in the ATR pathway through its interaction with the RPA complex. 
Ajuba depletion caused phosphorylation of RPA32, an early event during ATR 
activation. Based on the results, we hypothesize that Ajuba protects RPA, by shielding it 
from checkpoint kinases and PIKKs, thereby preventing unwanted RPA32 
phosphorylation and RPA mediated activation of DDR. Ajuba was observed to co-
immunoprecipitate with RPA70 subunit in cells. So, another hypothesis could be that 
Ajuba specifically interacts with the N-terminus OB fold of RPA70. This region of 
RPA70 is required for its association with ATRIP and Rad9 subunit of RAD9-HUS1-
RAD1 (9-1-1) complex. ATR signaling is dependent on colocalization of the ATR-
ATRIP complex with the 9-1-1 complex. Hence, Ajuba could play a role in assembly of 
the proteins critical for ATR activation. Our lab is currently exploring if there is a direct 
interaction between RPA and Ajuba or if other proteins mediate it.  
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The interaction between RPA and Ajuba was found to be intact in unsynchronized and 
replicating cells, but was lost upon ATR activation. It would be interesting to uncover the 
exact mechanism of their dissociation. Chemical modification of proteins is known to 
change their activity by altering their affinities for binding proteins. It remains to be 
elucidated if exposure to genotoxic drugs weakens the RPA-Ajuba interaction through 
chemical modification.   
It is important to address if Ajuba exerts its function of DDR regulation specifically 
during S phase of the cell cycle, hence it is necessary to investigate the role of Ajuba 
during a single cell cycle.  A genetic analysis of Ajuba function could be performed 
through a fast depletion strategy using the degron-Shld system, which can deplete Ajuba 
within two hours. Cells can be synchronized in G1 by a double Thymidine block, and 
released into S phase followed by fast depletion of Ajuba. Since a normal S phase lasts 
about 8 hours in normal growth conditions, depletion of Ajuba should be sufficient to 
show an effect during S phase without influencing cell viability.  
This thesis explores the role of Ajuba in only the ATR kinase pathway. Future studies can 
investigate if Ajuba has implications on other DDR pathways as well.  
We detected an association between Ajuba and OB fold containing proteins, RPA and 
POT1 in cells. The OB folds of POT1 were required for this interaction. This highlights 
the importance of OB folds as docking sites for LIM proteins. OB folds are necessary for 
POT1 to bind to ssDNA and are required by POT1 in negative regulation of telomerase in 
cancer cells. Ajuba is present at human telomeres and is seen to associate with active 
telomerase in cells. This indicates a probable role of Ajuba in telomere length regulation. 
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Telomere length regulation is a complex process and is regulated by variety of proteins. 
Measuring telomere length in Ajuba depleted or Ajuba overexpressing cells might help in 
understanding the possible role of Ajuba at telomeres.  
Another intriguing question is how Ajuba localizes to chromatin to exert its nuclear role 
in DDR. Ajuba is mainly known to be a cytosolic protein, but previous studies reveal that 
it can translocate to the nucleus. It is possible that binding to specific protein partners 
influence its cellular localization. More research is needed to address this question. To 
explore this, exogenously expressed Ajuba isoforms can be transfected in human cells 
and its subcellular localization can be monitored in response to DDR.   
With in this study, we show a previously uncharacterized role of Ajuba in maintaining 
genomic stability. Further studies on the interactions involving Ajuba would give us a 
better understanding of Ajuba’s role in regulating cellular pathways and events, important 
for our understanding of cellular transformation in cancer. 
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